General Home Investors News

MedinCell receives a new grant to develop a best-in-class long-acting injectable product for HIV PrEP

By MedincellSeptember 4, 2019March 15th, 2024No Comments

MedinCell receives a new grant to develop a best-in-class long-acting injectable product for HIV PrEP

September 4, 2019

Previous PostThe MedinCell General Meeting votes to include the “Raison d’être” of the Company in its articles of association
Next PostMedinCell partners to address the untapped financial potential in Animal Health

Better medicine for all

Website by ScreenUp